Phaseline

Targets › B7H4

B7H4 (V-set domain-containing T-cell activation inhibitor 1): drug programs, companies and trials

2 programs from 2 companies in 5 trials: 2 Phase 3, 2 Phase 1, 1 Phase 2; Oncology; next expected readout Mar 2027.

Negatively regulates T-cell-mediated immune response by inhibiting T-cell activation, proliferation, cytokine production and development of cytotoxicity. When expressed on the cell surface of tumor macrophages, plays an important role, together with regulatory T-cells (Treg), in the suppression of tumor-associated antigen-specific T-cell immunity. (UniProt, Q7Z7D3)

Open in Phaseline: the race on B7H4, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Hansoh BioMedical R&D CompanyHS-20089
Anti-B7-H4 antibody-drug conjugate with topoisomerase I inhibitor payload
B7H4Phase 3Ovarian Cancer; Advanced Solid TumorsMar 2027
AstraZenecaPuxitatug Samrotecan (AZD8205)
B7-H4-targeted antibody-drug conjugate (ADC)
B7H4Phase 3Endometrial Cancer; Breast CancerSep 2027

Conditions

Ovarian Cancer (2) Advanced Solid Tumors (1) Endometrial Cancer (1) Breast Cancer (1)

Modalities

small molecule (1), mixed (1)

Companies

Hansoh BioMedical R&D Company (1) AstraZeneca (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.